Cabaletta Bio

This morning Cabaletta Bio reported positive initial clinical data from the Phase 1/2 RESET-Myositis™ and RESET-SLE™ trials of CABA-201. Read our press release on the News & Media section of our website and join our live investor conference call and webcast today at 8:00 a.m. EDT here: https://lnkd.in/eFsVhdxz #CART #celltherapy #myositis #SLE #autoimmune

Cabaletta Bio's Phase 1/2 RESET-SSc trial is now recruiting individuals with systemic sclerosis. The study is evaluating the safety and efficacy of CABA-201, an investigational CD19-CAR T cell therapy. Systemic sclerosis is a rare autoimmune disease that can affect the skin and organs in the body such as the heart, lungs and kidneys. Learn more at the link below: https://lnkd.in/eUf5J3-Y #CART #celltherapy #autoimmune #scleroderma #SSc

Join us at our Satellite Symposium on June 14th at 8:15am CEST at the #EULAR2024 Congress in Vienna, Austria. We will have presentations from Georg Schett, a pioneer of CAR T cell therapy for the treatment of autoimmune diseases, and Carl June, a pioneer of the first CAR T cell therapy approved in oncology, as well as David J. Chang, MD, MPH, FACR, our Chief Medical Officer, sharing our initial clinical data with CABA-201 in myositis and lupus. Look forward to seeing you there! #EULAR2024 #CART #celltherapy #autoimmune

Join us at our Satellite Symposium on June 14th at 8:15am CEST at the #EULAR2024 Congress in Vienna, Austria. We will have presentations from Georg Schett, a pioneer of CAR T cell therapy for the treatment of autoimmune diseases, and Carl June, a pioneer of the first CAR T cell therapy approved in oncology, as well as David J. Chang, MD, MPH, FACR, our Chief Medical Officer, sharing our initial clinical data with CABA-201 in myositis and lupus. Look forward to seeing you there! #EULAR2024 #CART #celltherapy #autoimmune

Cabaletta Bio's Phase 1/2 RESET-MG trial is now recruiting individuals with generalized myasthenia gravis. The study is evaluating the safety and efficacy of CABA-201, an investigational CD19-CAR T cell therapy. Myasthenia gravis is an autoimmune disease that results from antibodies that get in the way of signals between nerves and muscles, causing profound muscle weakness. Learn more at the link below: https://lnkd.in/ef9K3HW3 #CART #celltherapy #autoimmune #myastheniagravis #MG

Cabaletta Bio was grateful to be recognized on Tuesday night as the Healthcare Innovator of the Year at the 2024 Enterprise Awards hosted by the Philadelphia Alliance for Capital and Technologies (PACT). The shared vision and teamwork of the Crew have facilitated and accelerated our ability to develop potentially curative engineered cell therapies for patients with autoimmune disease. It is a privilege to be able to serve patients, families, and providers with our Crew members as part of the ecosystem across the region advancing innovative solutions within healthcare #PACT #2024EnterpriseAwards #CART #celltherapy #autoimmunedisease

Our publication describing the preclinical work for CABA-201, a fully human 4-1BBz anti-CD19 CART for refractory autoimmune diseases, was recently published in Molecular Therapy Methods and Clinical Development. https://lnkd.in/e7h9kt8a

We are looking forward to the EULAR 2024 Congress in Vienna, Austria. Join us at our Satellite Symposium on Friday, June 14th at 8:15am CEST for an exclusive and interactive presentation from Georg Schett, a pioneer of CAR T cell therapy for the treatment of autoimmune diseases, Carl June, a pioneer of the first CAR T cell therapy approved in oncology, and David J. Chang, MD, MPH, FACR, our Chief Medical Officer who oversaw the development of the only 2 products approved for systemic lupus erythematosus in the United States in over 60 years. You can also find us during the conference at Booths S18 and S19 in Hall B. We look forward to seeing you there! #EULAR2024 #CART #celltherapy #autoimmune

Cabaletta Bio reported no CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials. We are looking forward to presenting initial clinical data on those patients at a satellite symposium at the EULAR 2024 Congress in June. Read our Q1 2024 earnings press release here: https://lnkd.in/eTSPtw29 #CART #celltherapy #myositis #SLE #autoimmune

Cabaletta Bio is attending the Myasthenia Gravis Foundation of America (MGFA) 2024 National Patient Conference in Tampa, FL! Come see us at booth 17 to learn more about Cabaletta Bio and our ongoing clinical trials. #Myastheniagravis #MGFA #MG